Background of lentigo maligna

History

Sir Jonathan Hutchinson first described the concept of lentigo maligna in 1890. He noted a ‘senile freckle’ with progressive radial growth that he speculated had an infectious origin. The condition was subsequently further characterized as ‘circumscribed precancerous melanosis’ by Debreuilh in 1912 [1].

Clinical presentation, risk factors, and genetics

Lentigo maligna most commonly presents on the head and neck region of elderly patients, with the highest incidence in the seventh and eighth decades of life. It usually starts as a tan-brown macule or patch, but can have a variegated pigmentation with dark black or even amelanotic features (Figure 1A). It is slow-growing and usually progresses in a prolonged radial growth phase before entering into a vertical growth phase. Lentigo maligna can develop de novo or within a pre-existing solar lentigo. Patients typically present with a chief complaint of a new, asymptomatic pigmented macule or patch on the head or neck region, or a freckle that has changed in size, shape, or color.

Risk factors for development of lentigo maligna include the following: a history of sunburns, a history of nonmelanoma skin cancers, advanced age, lighter skin types, and tendency to form solar lentigines. Although lentigo maligna occurs on chronically sun-damaged skin, it is thought that intermittent sunburns, rather than cumulative sun exposure, are a risk factor for lentigo maligna [2].

Studies have shown that lentigo maligna has a different genetic make-up than other types of melanoma. Unlike the other types of melanoma, a genetic propensity to form atypical nevi is not seen in lentigo maligna. In lentigo maligna, there is a higher incidence of p53 mutations compared with BRAF mutations. BRAF may not play a significant role in lentigo maligna as it does with other types of melanoma [3–5].

Risk of progression and recurrence

Historically, lentigo maligna has been described as a premalignant precursor to invasive melanoma, and variations in nomenclature have caused confusion regarding its malignant potential [6]. In addition, early case series suggested that lentigo maligna melanoma carried a better prognosis than other types of melanoma [7]. However, it is now widely accepted that lentigo maligna represents the in situ phase of lentigo maligna melanoma, which is staged in the same way as
other types of melanoma using the American Joint Committee on Cancer (AJCC) guidelines, and its prognosis is directly related to the depth of invasion and other adverse features, such as high mitotic rate and ulceration [8].

No prospective study has been performed to examine the risk of progression of lentigo maligna to lentigo maligna melanoma. Limited data suggest that, if left untreated, lentigo maligna may progress to invasive melanoma in 30–50% of cases [9]. Some authors, however, postulate that this is an overestimation of progression. Weinstock and Sober performed an epidemiologic statistical analysis of the incidence and prevalence of melanoma [10]. They determined that a patient with a new diagnosis of lentigo maligna at the age of 45 would have a 3.3% risk of developing melanoma by the age of 75. Such a risk would be reduced to 1.2% if the new diagnosis was made at the age of 65. They hypothesized that one reason for the overestimation of progression is due to the fact that lentigo maligna is slow-growing, and patients typically only present when a new dramatic feature develops within the lesion. The true risk of progression is unknown, and a prospective study with a large cohort and a long follow-up duration is warranted to address this problem.

Similar to the risk of progression, the rate of progression of lentigo maligna to lentigo maligna melanoma has not been well-studied and has been estimated to range from 10 to 50 years. However, there are isolated case reports of rapid progression to invasive and metastatic melanoma from a few months to a few years [11–13].

Lentigo maligna recurrence rate varies with the treatment modality. The lowest rates of recurrence are quoted with microscopically controlled excision, which will be discussed in detail below. Recurrence is related to the fact that atypical melanocytes have subclinical extension beyond the clinical margin, which is only detected on a microscopic level. Numerous studies have shown that 5 mm margins excised around lentigo maligna are often insufficient to obtain margin control [14–26]. Agarwal et al. [15] sought to determine if 5 mm margins were adequate to excise lentigo maligna in 92 cases. They found that 58% of cases required wider excisions than 5 mm. DeBlooom et al. [16] illustrated the consequences of incomplete margin control; 22% (19/84) of melanoma in situ recurred as invasive (average Breslow depth of 0.94 mm) and 33% (8/24) of invasive melanoma recurred thicker (Breslow depth went from 1.53 to 2.83 mm). In a prospectively collected series of 1072 patients with 1120 melanoma in situ treated with Mohs micrographic surgery (MMS), Kunishige et al. showed that 6 mm margin excision achieved 86% clear margin, while 9 mm achieved 98.7% clear margin [17]. This study suggests that even melanoma in situ on the trunk and extremities should be excised with a 9 mm margin rather than a 5 or 6 mm margin to provide the higher cure rate.

Diagnosis

The diagnosis of lentigo maligna is challenging, as the clinical presentation can be subtle and varied. Early detection of lentigo maligna relies on a high clinical suspicion index. Several noninvasive methods are employed to facilitate early diagnosis of lentigo maligna, including dermoscopy, Wood’s lamp examination, and reflectance confocal microscopy. Histological evaluation, aided by immunohistochemistry staining if indicated, remains the gold standard for the confirmation of the diagnosis.

Dermoscopy

Dermoscopy utilizes a conventional or polarized light source to examine lesions with 10X magnification. The differential diagnosis of lentigo maligna includes pigmented actinic keratoses, benign solar lentigo, pigmented seborrheic keratoses, and lichen planus-like keratoses [27]. Also, early lentigo maligna may not exhibit the telltale signs of an evolving melanoma (changes in asymmetry, border, color, diameter), and it is often difficult to distinguish from surrounding sun-damaged skin [28]. Dermoscopy can help aid the clinician in the differentiation between benign entities and lentigo maligna.

Studies have shown improved diagnosis of lentigo maligna with dermoscopy. Tschandi et al. performed a prospective study of 240 flat, pigmented facial lesions to better characterize dermoscopic patterns of these lesions. Twenty-four of these lesions were histopathologically lentigo maligna [29]. The positive predictive value for lentigo maligna was highest for a pattern of circles. In addition, the presence of a gray color is a clue to malignancy regardless of pattern [29]. Other features that have been noted to be found with lentigo maligna include the following: asymmetric pigmented follicular openings, dark rhomboidal structures, slate-gray globules, dots and streaks, annular-granular pattern, and black blotches [28,30].

Of note, pigmented actinic keratoses on the face are frequently diagnosed as lentigo maligna as both share many dermatoscopic features. This can result in unnecessary biopsies. Nascimento et al. [31] sought to further investigate the significance of an inner gray halo to help differentiate between pigmented actinic keratoses and lentigo maligna. The inner gray halo is a subtle gray or beige halo that surrounds follicular openings and meshes with the pseudonetwork that is characteristic of pigmented actinic keratoses.

Overall, dermoscopy can be a helpful tool to help differentiate lentigo maligna from other entities; however, sensitivity and specificity depends on the level of clinician expertise [32]. Therefore, all clinical factors need to be taken into account before the decision is made to perform biopsy.

Wood’s lamp examination

The Wood’s light was invented in 1903 and has since been a useful tool in the evaluation of pigmented lesions. The light is produced through the use of a filter that is opaque to all radiation except for a wavelength between 320 nm and 400 nm, with a peak at 365 nm. Melanin absorbs wavelengths of
Figure 1A. Lentigo maligna was diagnosed with a 4 mm punch biopsy on the left cheek. Close examination under the Wood’s lamp showed that the small biopsy was within a large brown patch with color variegation and ill-defined margin, and multiple scattered brown macules.

Figure 1B. Multiple scouting biopsies were taken from the pigmented patch and macules for histological evaluation. Among twelve sampled areas, five were lentigo maligna, one was atypical junctional melanocytic proliferation, and the rest were pigmented actinic keratoses.

Figure 1C. Design for the first stage slow Mohs excision. A 3 mm margin debulking excision was taken down to subcutaneous fat for evaluation of Breslow depth via vertical sectioning, and another 3 mm margin was taken down to deep subcutaneous fat or fascia for complete margin evaluation via horizontal en-face sectioning.

Figure 1D. Defect after the first stage slow Mohs excision.

Figure 1E. Partial simple closure after the first stage slow Mohs excision before the patient was discharged home.

Figure 1F. A narrow strip of control skin was taken from the contralateral, normal appearing, sun-damaged area and submitted for en-face sectioning.
Radiation from 350 to 1200 nm, which spans visible, infrared, and ultraviolet light. Observation of melanin under visible light is suboptimal to discern between normal skin and lightly pigmented lesions. Visible light contains longer wavelengths, which have a deeper penetration into the dermis; these longer wavelengths are scattered by the dermis, which lowers the contrast of the pigment perceived by the naked eye. Lesions possessing an increased concentration of epidermal melanin will appear darker and fluoresce under Wood’s light. This occurs because the Wood’s light utilizes only shorter wavelengths, which improves the contrast between epidermal melanin and normal skin [33].

Since the true margins of lentigo maligna can exist far beyond the margins seen with visible light, the Wood’s light is used to improve margin delineation. The depth of melanin determines the amount of fluorescence seen with the Wood’s light. Shorter wavelengths do not penetrate the dermis; therefore, dermal melanin is not accentuated [34]. For maximum effect, the Wood’s light should be used in a dark, windowless room. It is also very useful for examination of pigment recurrence in scars from previous lentigo maligna excisions [35].

Reflectance confocal microscopy

Reflectance confocal microscopy (RCM) is a noninvasive imaging technique that can detect characteristic histological features related to lentigo maligna. Confocal microscopes image thin sections of living, intact tissue with high contrast and resolution that is comparable to standard histology. These optical sections are obtained with a 100X microscope objective. This allows for evaluation of tissue architecture at the nuclear and cellular level without a biopsy [36].

Tannous et al. [37] described findings from RCM in cases of lentigo maligna compared with normal skin. In clinically normal skin, melanocytes have a bright cytoplasm and are small, with a small nuclear to cytoplasmic ratio and round nuclei. Normal melanocytes are dispersed widely as single cells at the level of the basal layer of the epidermis. In lentigo maligna, there is an increased number of larger melanocytes present as single cells at the dermoepidermal junction; these have large, angulated nuclei with a high nuclear to cytoplasmic ratio. Discrete nests and pagetoid spread of atypical melanocytes can be seen. Lentigo maligna and lentigo maligna melanoma exhibit an intraepidermal proliferation of dendritic cells, characterized by folliculotropism. This feature is rarely seen in benign lesions. Lentigo maligna and lentigo maligna melanoma can also exhibit unique ‘medusa-head like structures’ under confocal microscopy. These structures consist of elongated buds that extend from the hair follicle and are populated by dendritic or pleomorphic cells. They typically correspond to clinical asymmetric follicular pigmentation or a pseudonetwork [38].

One limitation is that the maximum depth of imaging is up to the upper reticular dermis, making it inadequate to evaluate invasive melanoma. Another limitation is the lack of availability and the need for specialized training in order to interpret images. Histological analysis of the tissue remains the gold standard for diagnosis of lentigo maligna. However, RCM could potentially act as an adjunctive tool to minimize the sampling error associated with biopsy [39].

Biopsy

Excisional biopsy is ideal for diagnosis of lentigo maligna [40]. In theory, excisional biopsy removes the whole clinical lesion down to subcutaneous fat with a 1–3 mm margin. This potentially allows for complete evaluation of depth and peripheral involvement. Excisional biopsy, however, is often not feasible for lentigo maligna because the
Figure 2A. Hematoxylin and eosin stain of the original biopsy of an eyelid lentigo maligna demonstrated classic lentigo maligna or melanoma in situ. There are an increased number of melanocytes at the dermoepidermal junction forming nests, as well as presenting as single cells with mildly enlarged, hyperchromatic nuclei (10X).

Figure 2B. The higher power of 2A (20X).

Figure 2C. An example of positive histological margin of lentigo maligna following slow Mohs excision. Immunohistochemistry stains using MART-1 (and MiTF, another melanocytic marker; photos not shown) strongly highlight an increased number of melanocytes at the dermoepidermal junction. There is multifocal confluence and there are scattered small nests. There is also prominent extension along adnexal epithelium.

Figure 2D. An example of histological morphology of normal appearing, chronically sun-exposed skin taken from the patient’s contralateral cheek. In this control skin, there is also a moderately increased number of melanocytes, some of which confluent, but there are no nests or pagetoid spreads.
lesions are typically ill-defined, widespread, and located in cosmetically sensitive areas. If the size of the lesion limits the ability to perform an excisional biopsy, shaving or punch biopsies can be performed (Figure 1B). Scouting biopsies should include samples from the darkest part, or most concerning part of the lesion, which will minimize the sampling error. They can also be taken from the periphery of the lesion to help delineate the peripheral margin involvement (Figure 1B).

**Histological examination**

Microscopic findings of lentigo maligna are characterized by the following features: atypical melanocytic hyperplasia at the dermoepidermal junction, confluence of atypical melanocytes and angulated nuclei replacing the basal layer, and nesting of atypical melanocytes with occasional pagetoid spread (Figures 2A and 2B). The cells often show cytoplasmic retraction, and there is adnexal involvement of atypical melanocytes. There can be rete ridge effacement and epidermal atrophy, but these features are not required for diagnosis of lentigo maligna [41].

Histopathologic diagnosis has been historically challenging due to the fact that it is difficult to distinguish lentigo maligna from sun-induced melanocytic hyperplasia that is naturally present on sun-damaged skin [42]. Biopsy taken from normal appearing, sun-damaged skin helps the pathologist to establish the baseline melanocytic hyperplasia for each particular patient.

Immunohistochemical (IHC) stains are often used to aid in the diagnosis of lentigo maligna. Melanoma antigen recognized by T cells (MART-1 also known as Melan A) and microphthalmia transcription factor (MiTF) are the two stains regularly used at our institution. MiTF is expressed in the nucleus of melanocytes. It accurately highlights the number of melanocytes seen in the epidermis and lesions of lentigo maligna. MART-1 may cause overestimation of the number of melanocytes in the epidermis due to the fact that MART-1 stains the cytoplasm of melanocytes, dendritic processes, and occasional keratinocytes [43]. Of note, MiTF and MART-1 are expressed in both benign and malignant melanocytes, further complicating the histological picture for the dermatopathologist [44]. Sox10 is also a useful tissue biomarker in melanocytic lesions [45,46]. It is present in the nucleus and regulates MiTF expression; therefore, similar to MiTF, it facilitates identification of melanocytes in the epidermis and chronically sun-damaged skin. MiTF and Sox10 have both been shown to be useful to distinguish lentigo maligna from pigmented actinic keratosis [47].

One promising, recently reported, IHC stain utilizes an antibody against soluble adenylyl cyclase (R21). Soluble adenylyl cyclase (sAC) is over-expressed in the nuclei of lentigo maligna, but not in native melanocytes [48]. With R21, nuclear expression of sAC is detected in almost 90% cases of lentigo maligna, but not in nevi. However, 25–30% of melanocytic hyperplasia in benign lentigines can show nuclear staining of sAC, which then needs to be distinguished from lentigo maligna with the hematoxylin and eosin stain [49]. R21 is not widely used currently, but may become a promising adjunct to stains such as MART-1 and MiTF to help differentiate lentigo maligna from benign melanocytic lesions.

Some authors have discussed the use of melanocyte count to help determine histological margins and predict risk of recurrence. Gorman et al. [50] showed that melanocyte count is a strong predictor of lentigo maligna recurrence; patients were divided into low, intermediate, and high-risk groups based on the melanocyte count.

**Treatment of lentigo maligna**

Surgical excision is the mainstay of treatment. National Comprehensive Cancer Network, a consensus group that develops evidence-based practice guidelines (http://www.nccn.org), has recognized that wide local excision with 0.5–1 cm margins is insufficient for lentigo maligna, as opposed to other types of melanoma in situ. Traditional wide local excision specimens are processed by the bread loaf technique (Figure 3). Standard bread loaf techniques result in vertical sections at 2–4 mm intervals, which allow examination of less than 0.01% of the specimen surface area [51]. In order to examine 100 percent of the margin, vertical sections would have to be performed every 0.1 mm, which would be technically difficult [52]. Therefore, wide local excision processed by bread loaf technique is not ideal for complete margin control of lentigo maligna, in which the background of melanocytic hyperplasia often obscures the true borders of the lesion both clinically and histologically. In studies that include treatment of lentigo maligna with MMS and staged excision, it is not uncommon to find that greater than 1 cm margin is required to achieve histologically negative margins. In addition, 5–52% of lesions diagnosed initially as melanoma in situ had a dermal invasive component discovered at re-excision [53], further indicating the inadequacy of pre-determined excision margins. For these reasons, surgical excisions followed by more complete histological assessment of margins are preferred in the management of lentigo maligna, examples of which include traditional frozen-section MMS and staged excision aided by paraffin-embedded, permanent sections.

**Mohs micrographic surgery**

MMS is a well-developed surgical technique ideal for treatment of different types of skin cancers that grow in a contiguous fashion [54]. It is a tissue-sparing technique that allows for complete and immediate examination of the entire peripheral margin around the skin cancer (Figure 4). Dr. Frederic Mohs at the University of Wisconsin–Madison first developed the idea in the 1930s when he discovered that 20% zinc chloride solution injected into tumors of rats...
Figure 3. Schematic illustration of bread loaf sections for evaluating tissue margins. Vertical sections 1, 2, 3 are taken from the middle and at both ends of tissue blocks (A, B, C, and D). All three vertical sections appear clear of tumor; however, there is residual cancer in block B that is not included and therefore missed in representative vertical sections, creating a false negative margin (reprinted with permission from Dr. Stephen Snow, *Mohs Micrographic Surgery*, 2nd Edition, The University of Wisconsin Press, 2004).

Figure 4. Schematic illustration of horizontal en-face sections of tissue during Mohs micrographic surgery. Tissue blocks A and B were processed horizontally from deeper portion of the specimen toward the superficial portion representing epidermis. Each horizontal sectioning includes the deep and lateral edges for a complete margin evaluation. Cancer is found toward the center of the tissue block B, which is documented with color-coding in a map for orientation of each block (reprinted with permission from Dr. Stephen Snow, *Mohs Micrographic Surgery*, 2nd Edition, The University of Wisconsin Press, 2004).
showed well-preserved cell histology. He used a fixed-tissue technique for over a decade to excise tumors under complete microscopic margin control. The technique then evolved to the use of horizontal frozen sections in the 1950s and 60s, which then widely replaced the fixed-tissue technique [55]. Dermatological surgeons are the primary practitioners of MMS, in which they play a dual role of surgeon and pathologist. MMS is widely used and accepted for excision of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma in cosmetically sensitive areas, but is also used by some dermatological surgeons for excision of lentigo maligna and lentigo maligna melanoma. Although the use of MMS for lentigo maligna is controversial, it is included in the AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for MMS [56].

The excision of lentigo maligna with MMS usually occurs during one working day. The clinically apparent lesion is outlined and then excised; this debulk section is sent for paraffin-embedded, permanent sections to examine for possible invasion. Then, a margin of tissue is excised around this debulk area with a scalpel positioned at a 45-degree angle. The 45-degree inward bevel allows the tissue to lie down in a way that facilitates en-face processing (parallel to the surgical margin). Scores are made on the skin edge with the scalpel and correspond to the orientation of the tissue. The tissue is then divided into sections and inked for frozen-section en-face processing. The orientation and inking pattern of individual sections are recorded on a map. The processing and evaluation of the tissue takes a variable amount of time, usually 0.5–2 hours. This also may take longer depending on the need for special stains.

The surgeon then analyzes the slides and carefully documents areas on the peripheral or deep margin that show tumor. Tissue is excised only around the positive margin, thereby sparing excision of normal tissue. This process is repeated until the margins are clear of tumor [54,57]. When histologically negative margins are achieved, the patient can have reconstruction either on the same day or within the following few days.

Published rates of recurrence for lentigo maligna and lentigo maligna melanoma treated with MMS range from 0 to 6.25% [57–69], except for one study that reported a recurrence rate as high as 33% with MMS (6/18), as compared with 7.3% (3/41) with staged excision during a mean follow-up time of almost 10 years [59]. The authors admitted that the small amount of MMS cases performed and ascertainment technique likely contribute to the high recurrence rate. In contrast, Bricca et al. [62] reported a 5-year recurrence rate of 0.2% in a prospective study of 625 patients who underwent MMS for lentigo maligna and lentigo maligna melanoma. This study included updated data from previous studies, in which the authors had extensive experience with MMS for lentigo maligna [57,68–70]. This discrepancy in cure rates highlights why the use of MMS for lentigo maligna remains controversial. The key limiting factor is the accuracy of interpretation of melanocytic lesions on frozen-section histology. Certain cytoplasmic features that may help distinguish lentigo maligna such as perinuclear retraction are lost under frozen-section processing [71]. Frozen-section processing also alters the morphology of keratinocytes and produces halos that mimic melanocytes, adding to the error in recognizing tumor cells. As early as 1991, Zitelli’s group reported 100% sensitivity and 90% specificity in detecting atypical melanocytes at the margins of melanoma with frozen sections, using permanent sections as a gold standard [72]. However, other investigators have reported lower accuracy; Barlow et al. report a sensitivity of 59% and specificity of 81% [71]. Inevitably, the validity of using frozen sections to assess melanoma margins has been challenged because interpretation of melanoma excision margins on frozen sections depends heavily on the level of experience of the individual surgeon. Therefore, frozen-section histology is generally disputed and discouraged by an overwhelming majority of physicians involved in the treatment of melanoma.

To aid in intra-operative margin control during MMS excision for melanoma, a variety of IHC stains have been studied that highlight melanocytes, including S-100, HMB-45, MART-1, Mel-5, and MiTF. Among all tested markers, MART-1 and MiTF are proving more useful than others. In contrast to their established value in permanent sections, their use in frozen sections during MMS has remained restricted to a limited number of Mohs surgeons. A survey of 378 fellowship-trained Mohs surgeons revealed that approximately 90% responders felt that IHC on frozen sections were helpful while only about 22% were using it in practice [73]. Extra time involved with tissue processing, along with the lack of education and cost, are the main deterrents for a wider adoption of immunostain during MMS. The time needed to perform immunostain protocols has improved over the past decade from over 2 hours to less than 1 hour [74]. Few rapid protocols are available for MART-1 with the reported duration as short as 16 minutes [75–77]. A 35-minute protocol is reported for MiTF [78]. It raised another concern as to whether an inappropriately shortened duration may lead to an inflated, false negative rate in margin assessment.

**Staged excision**

Staged excision relies on paraffin-embedded, permanent sections rather than frozen sections for histological evaluation of surgical margins. Various staged excision techniques have been proposed in an attempt to identify a valid and reliable method in excising lentigo maligna and lentigo maligna melanoma with clear margins: ‘square method’ [22,79,80], ‘perimeter technique’ or ‘spaghetti technique’ [15,21,81], ‘slow Mohs’ [66], staged radial sections [24,53] and staged ‘mapped’ excisions [23,25,26,59]. Favorable recurrence rates of 0–12% have been reported in several case series with follow-up duration ranging from 4 months to 5 years (Table 1) [14,15,18–26,80–84]. The highest recurrence rates were found in the two studies with the longest follow-up of 5 years: 4.8% [24] and 12% [83]. Staged excision offers greater margin control than standard surgical excision and avoids some of the pitfalls related to MMS with frozen sections.
At our institution, staged excision with en-face permanent sections is the treatment of choice for lentigo maligna, also known as ‘slow Mohs’ excision. The first stage involves taking a 6 mm margin around the clinical lesion (Figure 1C), which has been described by Zitelli et al. with frozen sections [68,69]. First, the clinical margin of the lentigo maligna is outlined taking into account the clinical appearance with natural light, Wood’s lamp examination, and the histopathologic diagnosis of previous scouting biopsies. Second, a central debulk specimen is excised by taking 3 mm of clinically normal skin around the outlined lesion to the depth of superficial subcutaneous fat. This debulk specimen is submitted separately for paraffin-embedded, permanent sections and is vertically sectioned using bread loaf technique to assess Breslow depth. Third, an extra 3 mm margin is marked lateral to the debulk defect; this is excised with a scalpel angled at 45 degrees as a single piece down to deep subcutaneous fat or fascia (Figure 1D). The 12 o’clock position is scored on the specimen and sutured on the patient to preserve orientation. In the same way as with MMS, the excised specimen is then divided in a way that facilitates accurate processing by the histotechnicians. Each subsection is inked, placed in a separate tissue cassette, and processed with en-face paraffin-embedded, permanent sections for complete margin evaluation. A map is drawn that specifically outlines orientation and color-coding of the individual subsections of the specimen. If warranted, a partial closure is performed to obtain hemostasis and simplify wound care for the patient while awaiting histological evaluation of the margin status (Figure 1E). In addition, a narrow strip of normal appearing, sun-damaged skin is often taken as a control, usually from the contralateral side of the face (Figure 1F).

The permanent vertical sections of the central debulk specimen and en-face sections of the ‘slow Mohs’ specimens are examined by experienced dermatopathologists. Results are usually available in 24–48 hours. If indicated, MART-1 and MiTF are used at our institution to aid in diagnosis, which add another 2 to 3 days to the histological analysis of the tissue. If the debulk specimen confirms the presence of lentigo maligna or reveals no remaining cancer but scar tissue, there is no change in the diagnosis of lentigo maligna. However, if the debulk specimen demonstrates an invasive component, the Breslow depth and
other pertinent histological features will be reported and the lesion will be upgraded to lentigo maligna melanoma and staged per AJCC guidelines. At our institution, stage 1A invasive lentigo maligna melanoma is still managed with ‘slow Mohs’ excision, while 1B and beyond will be referred to surgical oncology services for consultation for possible sentinel lymph node biopsy and additional wide local excision. It is worth noting that when treating lentigo maligna, or potentially upgraded lentigo maligna melanoma, ‘slow Mohs’ excision reaches a depth of deep subcutaneous fat or fascia. The authors have never encountered any positive tumor involving deep margins. If lateral surgical margins are positive, the patient returns for a second stage ‘slow Mohs’ excision. Another 3 mm margin is taken laterally around the positive area (Figure 1G). The specimen is again color-coded with ink, mapped, and sent to dermatopathology for en-face tissue processing and histopathologic analysis. If special stains are needed, this may prolong the time between stages or before repair. The process is repeated until clear peripheral margins are achieved. The final defects are often large and complicated due to subclinical spread of lentigo maligna and require coordinated reconstruction by plastic surgery or oculoplastic services (Figure 1H).

Different techniques of staged excision have been reported in the literature as mentioned. One main difference among various techniques is how the marginal tissue is processed. Some authors report serial vertical sectioning [53], while others use en-face permanent sections. The major advantage of en-face processing is that it allows for examination of 100 percent of the peripheral margin and minimizes the risk of missing radial extension of lentigo maligna. It also allows the surgeon to take additional excision stages only around involved margins, thereby sparing excision of normal tissue. One caveat is that en-face processing of tissue for permanent section can be difficult.

Therefore, it requires skilled staff, which may not be present at all institutions. Another challenge of en-face evaluation is that it does not allow assessment of the change in melanocyte density from the center of the lesion to the periphery, a feature that is helpful to differentiate between sun-damaged skin and lentigo maligna [85].

**Nonsurgical interventions**

**Imiquimod**

Imiquimod is a member of a class of immune response modifiers called imidazoquinolines. It is an immune response stimulator that enhances both the innate and acquired immune pathways (particularly T helper cell type 1-mediated immune responses). Imiquimod causes cytokine induction in the skin through induction of Toll-like receptors. This then triggers an inflammatory cascade that causes the host’s immune system to recognize and subsequently destroy tumor cells. An indirect effect of imiquimod is stimulation of interferon-gamma production from Th-1 cells, which thereby stimulates cytotoxic T lymphocytes [86]. Cytotoxic T cells are responsible for destruction of tumor and establishment of immunological memory for future protection [87].

Imiquimod is licensed in the United States and United Kingdom for treatment of genital warts, actinic keratoses, and superficial basal cell carcinoma. It is used off-label for lentigo maligna. Collected data suggest possible benefit but its efficacy in lentigo maligna has been evaluated only in limited, uncontrolled studies, case reports, and case series with relatively limited short follow-up of less than 5 years [88–101].

Although there is no evidence that imiquimod 5% cream is better than observation alone in patients who are elderly and/or cannot have a large surgical excision, it is often presented
as a treatment option given its beneficial outcome in certain cases. Nevertheless, it is important to discuss the risks and benefits of imiquimod with patients, including the lack of evidence, the risk of undertreating or masking a possible invasive melanoma, the risk of recurrence, and side effects such as inflammation. Some authors suggest that treatment course should be followed up by repeat biopsies [92]. Figures 5A and 5B represent a patient who had exuberant inflammatory response with imiquimod and disappearance of the clinical lesion after 2 months of treatment. Close follow-up is suggested for patients who use imiquimod, and biopsy should be strongly considered if there is ever recurrence of pigment or any development of induration.

**Radiation therapy**

Radiotherapy, like imiquimod, is a noninvasive treatment option that has been used as a primary treatment for lentigo maligna in patients who are poor surgical candidates. Studies have used Grenz ray therapy for treatment of lentigo maligna [102–104]. Data are limited regarding the use of radiotherapy, and long-term follow-up outcomes are lacking. Fogarty performed a retrospective analysis of all studies from 1941 to 2009 with a mean follow-up of 3 years; 18/349 (5%) lesions recurred [105]. Radiotherapy may be a promising option for the treatment of lentigo maligna; however, it is not widely utilized and prospective trials are needed.

**Miscellaneous treatments**

A recent Cochrane review discussed other treatments that have been used for lentigo maligna, including azelaic acid, lasers, electrodessication and curettage, cryosurgery, and 5-fluouracil 5% cream [106]. Currently, these methods are not recommended because they are only used anecdotally in limited studies, they don’t offer microscopic margin control, and they would likely not treat any periadnexal extension of lentigo maligna or lentigo maligna melanoma [107].

**Conclusion**

Lentigo maligna is a slow-growing melanoma in situ on the head and neck region. Clinical and histopathologic diagnosis of this entity is sometimes difficult. Clinically, the lesion may appear similar to benign diagnoses, such as a solar lentigo, seborrheic keratosis, pigmented actinic keratosis, lichen planus-like keratosis, or benign nevus. Histologically, atypical melanocytic hyperplasia present on normal, sun-damaged skin can sometimes appear very similar to lentigo maligna. Tools such as dermoscopy, Wood’s light examination, RCM, scouting biopsies for histopathologic, and IHC stains can help exclude benign findings and aid in the diagnosis of lentigo maligna. High-quality evidence is lacking for the treatment of lentigo maligna. Surgical interventions with complete margin control remain the gold standard, which include staged excision with rush permanent sections and MMS. Although these are considered the first-line therapy for this condition, there are no randomized controlled trials validating their use and showing long-term effects on morbidity and mortality. The use of nonsurgical interventions in selected patients who are not surgical candidates may be preferable. The nonsurgical intervention that has been most studied is topical imiquimod, although it also lacks high-quality evidence. It can be used by experienced providers with close patient follow-up. Sometimes repeat biopsies are needed to confirm clearance or monitor for recurrence. Radiation is a promising therapy for treatment of lentigo maligna, but more studies are needed to support its use.

When approaching patients with a new diagnosis of lentigo maligna, it is preferable to give them consultation before any procedure takes place. It is important to discuss the slow-growing nature of lentigo maligna and the risk of invasive disease. One must take the age and comorbidities of each individual patient into account when creating a treatment plan. Subclinical spread of lentigo maligna may create a large surgical defect with the need for extensive reconstruction to maintain acceptable cosmesis. Some patients may choose not to have surgery or are poor surgical candidates due to advanced age and comorbidities. If this is the case, second-line therapy with imiquimod, radiation, or close observation alone are acceptable alternatives to surgical management, as long as the patient understands all risks and benefits of each treatment option.

**Acknowledgments**

We thank our patients for their willingness to contribute to medical education. We appreciate Mr Gerald Keyser for taking photos of slides.
References

1. van Ruth S, Toonstra J. Eponyms of Sir Jonathan Hutchinson. Int J Dermatol. 2008;47(7):754–8. http://dx.doi.org/10.1111/j.1365-4632.2008.03696.x. PubMed PMID: 18613888

2. Gaudy-Marqueste C, Madjlessi N, Guillot B, Avril MF, Grob JJ. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol. 2009;145(4):418–23. http://dx.doi.org/10.1001/archdermatol.2009.1. PubMed PMID: 19380663

3. Purdue MP, From L, Kahn HJ, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD. Etiologic factors associated with p53 immunostaining in cutaneous malignant melanoma. Int J Cancer. 2005;117(3):486–93. http://dx.doi.org/10.1002/ijc.21196. PubMed PMID: 15900597

4. Sasaki Y, Niu C, Makino R, Kudo C, Sun C, Watanabe H, Matsunaga J, Takahashi K, Tagami H, Alba S, Horii A. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol. 2004;123(1):177–83. http://dx.doi.org/10.1111/j.0022-202X.2004.22722.x. PubMed PMID: 15191558

5. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95(24):1878–90. PubMed PMID: 14679157

6. Dubow BE, Ackerman AB. Ideas in pathology. Malignant melanoma in situ: the evolution of a concept. Mod Pathol. 1990;3(6):734–44. PubMed PMID: 2263599

7. Kelly JW. Following lentigo maligna may not prevent the development of life-threatening melanoma. Arch Dermatol. 1992;128(5):657–60. PubMed PMID: 1575529

8. Koh HK, Michalik E, Lew RA, Day CL, Clark W, Mihm MC, Kopf AW, Blois MS, Fitzpatrick TB. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol. 1984;2(9):994–1001. PubMed PMID: 6470757

9. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol. 2005;6(3):151–64. PubMed PMID: 15943492

10. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116(3):303–10. PubMed PMID: 3567069

11. Albert LS, Fewkes J, Sober AJ. Metastatic lentigo maligna melanoma. J Dermatol Surg Oncol. 1990;16(1):56–8. PubMed PMID: 2299024

12. Kelly RI, Cook MG, Mortimer PS. Aggressive amelanotic lentigo maligna. Br J Dermatol. 1994;131(4):562–5. PubMed PMID: 7947211

13. Michalik EE, Fitzpatrick TB, Sober AJ. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. Arch Dermatol. 1983;119(10):831–5. PubMed PMID: 6614952

14. Abdelmalek M, Loosmore MP, Hurt MA, Hruza G. Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review. Arch Dermatol. 2012;148(5):599–604. http://dx.doi.org/10.1001/archdermatol.2011.2155. PubMed PMID: 22782151

15. Agarwal-Antal N, Bowen GM, Gershels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47(5):743–8. PubMed PMID: 12399768

16. DeBloom JR 2nd, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. Dermatol Surg. 2010;36(8):1251–7. http://dx.doi.org/10.1111/j.1524-4725.2010.01618.x. PubMed PMID: 20666813
17. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol. 2012;66(3):438–44. http://dx.doi.org/10.1016/j.jaad.2011.06.019. PubMed PMID: 22196979

18. Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg. 2009;124(6):1947–55. http://dx.doi.org/10.1097/PRS.0b13e3181bcf002. PubMed PMID: 19952650

19. Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58(1):142–8. http://dx.doi.org/10.1016/j.jaad.2007.09.023. PubMed PMID: 18029055

20. Schrifter R, Schiffrin-Rohe J, Vogt T, Landthaler M, Wlotzke U, Cognetta AB, Stolz W. Improvement of early recognition of lentigo maligna melanoma using dermatoscopy. J Dermatol. 2004;31(9):1087–92. http://dx.doi.org/10.1010/archderm.140.9.1087. PubMed PMID: 15381549

21. Nascimento MM, Shitara D, Enokihara MM, Yamada S, Pellacani G, Rezze GG. Inner gray halo, a novel dermoscopic feature for lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140(9):1087–92. http://dx.doi.org/10.1001/archderm.140.9.1087. PubMed PMID: 15381549
40. Kallini JR, Jain SK, Khachemoune A. Lentigo maligna: review of salient characteristics and management. Am J Clin Dermatol. 2013;14(6):473–80. http://dx.doi.org/10.1007/s40257-013-0044-6. PubMed PMID: 24019181

41. Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med. 2014;138(6):759–87. http://dx.doi.org/10.5858/arpa.2013-0157-RA. PubMed PMID: 24878016

42. Montagna W, Kirchner S, Carlisle K. Histology of sun-damaged human skin. J Am Acad Dermatol. 1989;21(5 Pt 1):907–18. PubMed PMID: 2808826

43. Tetzlaff MT, Torres-Cabala CA, Pattanaprachakul P, Rapini RP, Prieto VG, Curry JL. Emerging clinical applications of selected biomarkers in melanoma. Clin Cosmet Investig Dermatol. 2015;8:35–46. http://dx.doi.org/10.2147/CCID.s49578. PubMed PMID: 25674009; PubMed Central PMCID: PMC4321413

44. Kim J, Taube JM, McCalmont TH, Glusac EJ. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-S in solar lentigines and melanoma in situ. J Cutan Pathol. 2011;38(10):775–9. http://dx.doi.org/10.1111/j.1600-0560.2011.01763.x. PubMed PMID: 21797290

45. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32(9):1291–8. http://dx.doi.org/10.1097/PAS.0b013e3181658c14. PubMed PMID: 18636017

46. Orduñez NG. Value of SOX10 immunostaining in tumor diagnosis. Adv Anat Pathol. 2013;20(4):275–83. http://dx.doi.org/10.1097/PAP.0b013e318291a9d0. PubMed PMID: 23752089

47. Buonaccorsi JN, Prieto VG, Torres-Cabala C, Suster S, Plaza JA. Diagnostic utility and comparative immunohistochemical analysis of MiTF-1 and SOX10 to distinguish melanoma in situ and actinic keratos: a clinicopathological and immunohistochemical study of 70 cases. Am J Dermatopathol. 2014;36(2):124–30. http://dx.doi.org/10.1097/DAD.0b013e318291485c. PubMed PMID: 23782678

48. Magro CM, Yang SE, Zippin JH, Zembowicz A. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and evaluation of margins. Arch Pathol Lab Med. 2012;136(12):1558–64. http://dx.doi.org/10.5858/arpa.2011-0617-OA. PubMed PMID: 23194049; PubMed Central PMCID: PMC3732207

49. Soltky AC, Zembowicz A. Soluble adenylyl cyclase antibody (R21) as a diagnostic adjunct in the evaluation of lentigo maligna margins during slow Mohs surgery. Am J Dermatopathol. 2014;36(11):882–7. http://dx.doi.org/10.1097/DAD.0000000000000074. PubMed PMID: 24698940

50. Gorman M, Khan MA, Johnson PC, Hart A, Mathew B. A model for lentigo maligna recurrence using melanocyte count as a predictive marker based upon logistic regression analysis of a blinded retrospective review. J Plast Reconstr Aesthet Surg. 2014;67(10):1322–32. http://dx.doi.org/10.1016/j.bjps.2014.05.058. PubMed PMID: 24939827

51. Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984;73(3):492–7. Epub 1984 Mar 1. PubMed PMID: 6701225

52. Kimyai-Asadi A, Katz T, Goldberg LH, Ayala GB, Wang SQ, Vujevich JJ, Jih MH. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. J Am Acad Dermatol. 2007;57(4):659–64. PubMed PMID: 17870430

53. McGuire LK, Disa JJ, Lee EH, Busam KJ, Nehal KS. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg. 2012;129(2):288e–99e. http://dx.doi.org/10.1097/PRS.0b013e31823ae352. PubMed PMID: 22864433

54. Snow SN, Madjar DD Jr. Mohs surgery in the management of cutaneous malignancies. Clin Dermatol. 2001;19(3):339–47. PubMed PMID: 11479046

55. Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med. 2014;138(6):759–87. http://dx.doi.org/10.5858/arpa.2013-0157-RA. PubMed PMID: 24878016

56. Ordóñez NG. Value of SOX10 immunostaining in tumor diagnosis. Adv Anat Pathol. 2013;20(4):275–83. http://dx.doi.org/10.1097/PAP.0b013e318291a9d0. PubMed PMID: 23752089

57. Trost LB, Bailin PL. History of Mohs surgery. Dermatol Clin. 2011;29(2):135–9. PubMed PMID: 21421139

58. Ad Hoc Task F, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50. http://dx.doi.org/10.1016/j.jaad.2012.06.009. PubMed PMID: 22959232

59. Zitelli JA, Mohs FE, Larson P, Snow S. Mohs micrographic surgery for melanoma. Dermatol Clin. 1989;7(4):833–43. PubMed PMID: 2676291

60. Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg. 2008;34(5):660–4. http://dx.doi.org/10.1111/j.1524-4725.2007.34124.x. PubMed PMID: 18261099

61. Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 2007;57(4):659–64. http://dx.doi.org/10.1016/j.jaad.2007.02.011. PubMed PMID: 17870430

62. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94(4):287–92. http://dx.doi.org/10.1002/jso.20305. PubMed PMID: 16917877

63. Bhaward S, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg. 2006;32(5):690–6; discussion 6–7. http://dx.doi.org/10.1111/j.1524-4725.2006.32142.x. PubMed PMID: 16706765
62. Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(1):92–100. http://dx.doi.org/10.1016/j.jaad.2004.08.038. PubMed PMID: 15627086

63. Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003;7(1):25–30. http://dx.doi.org/10.10227-002-1161-7. PubMed PMID: 12447624

64. Etzkorn JR, Sobanko JF, Elenitsas R, Newman JG, Goldbach H, Shin TM, Miller CJ. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol. 2015;72(5):840–50. http://dx.doi.org/10.1016/j.jaad.2015.01.007. PubMed PMID: 25774012

65. Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26(8):771–84. PubMed PMID: 10940065

66. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24(6):673–7. PubMed PMID: 9648576

67. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994;31(1):79–85. PubMed PMID: 8021377

68. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(2 Pt 1):236–45. PubMed PMID: 9270510

69. Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3 Pt 1):422–9. PubMed PMID: 9308558

70. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg. 1995;21(4):285–90. PubMed PMID: 7728476

71. Barlow RJ, White CR, Swanson NA. Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br J Dermatol. 2002;146(2):290–4. PubMed PMID: 11903242

72. Zitelli JA, Moyer RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol. 1991;24(1):102–6. PubMed PMID: 1999507

73. Trimble JS, Cherpelis BS. Rapid immunostaining in Mohs: current applications and attitudes. Dermatol Surg. 2013;39(1 Pt 1):56–63. http://dx.doi.org/10.1111/dsu.12015. PubMed PMID: 23121999

74. Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30(3):403–8. PubMed PMID: 15008870

75. Cherpelis BS, Moore R, Ladd S, Chen R, Glass LF. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg. 2009;35(2):207–13. http://dx.doi.org/10.1111/j.1524-4725.2008.34411.x. PubMed PMID: 19215257

76. Chang KH, Finn DT, Lee D, Bhawan J, Dallal GE, Rogers GS. Novel 16-minute technique for evaluating melanoma resection margins during Mohs surgery. J Am Acad Dermatol. 2011;64(1):107–12. http://dx.doi.org/10.1016/j.jaad.2010.02.055. PubMed PMID: 21167405

77. Kimyai-Asadi A, Ayala GB, Goldberg LH, Vujevich J, Jih MH. The 20-minute rapid MART-1 immunostain for malignant melanoma frozen sections. Dermatol Surg. 2008;34(4):498–500. http://dx.doi.org/10.1111/j.1524-4725.2007.34095.x. PubMed PMID: 18248466

78. Glass LF, Raziano RM, Clark GS, Higgins HW, Ladd S, Lien MH, Chen R, Cherpelis BS. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor. Am J Dermatopathol. 2010;32(4):319–25. PubMed PMID: 20514666

79. Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3(3):202–6. PubMed PMID: 11497507

80. Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37(5 Pt 1):758–64. PubMed PMID: 9366823

81. Gaudy-Marqueste C, Perchenet AS, Taséi AM, Madjlessi N, Magalon G, Richard MA, Grob JJ. The “spaghetti technique”: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol. 2014;70(3):570–6. http://dx.doi.org/10.1016/j.jaad.2013.12.036. PubMed PMID: 24939410

82. Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic surgery with melanoma antigen recognized by T cells (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol. 2015;72(5):840–50. http://dx.doi.org/10.1016/j.jaad.2015.01.007. PubMed PMID: 25774012

83. Lawrence CM, Rahim R, Charlton F, Husain A. Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results. Br J Dermatol. 2011;164(1):116. PubMed PMID: 21957304

84. Clayton BD, Leshin B, Hitchcock MG, Marks M, White WL. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg. 2000;26(7):671–8. PubMed PMID: 10868277

85. Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, Guitart J, Horenstein MG, Ming ME, Piep-korn MW, Rabkin MS, Reid JA, Selim MA, Trotter MJ, Johnson MM, Shea CR. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol. 2003;120(2):203–8. http://dx.doi.org/10.1309/J10-Q-V58E-UTMV-R193. PubMed PMID: 12931550

86. Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16(2):85–9. http://dx.doi.org/10.1097/01.aco.0000065075.06965.df. PubMed PMID: 12734440
87. Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151(4):903–6. http://dx.doi.org/10.1111/j.1365-2133.2004.06176.x. PubMed PMID: 15491436

88. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143(4):843–5. PubMed PMID: 11069469

89. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol. 2008;144(7):943–5. http://dx.doi.org/10.1001/archderm.144.7.943. PubMed PMID: 18645150

90. Hyde MA, Hadley ML, Tristani-Firouzi P, Gouldar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148(5):592–6. http://dx.doi.org/10.1001/archdermatol.2012.270. PubMed PMID: 22431716

91. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149 Suppl 66:66–70. PubMed PMID: 14616356

92. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143(4):843–5. PubMed PMID: 11069469

93. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol. 2008;144(7):943–5. http://dx.doi.org/10.1001/archderm.144.7.943. PubMed PMID: 18645150

94. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol. 2006;155(4):653–6. http://dx.doi.org/10.1111/j.1365-2133.2006.06876.x. PubMed PMID: 16954511

95. Ramsdell AM, Zeitouni N. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod. Dermatol Surg. 2009;35(2):287–90. http://dx.doi.org/10.1097/DSS.0b013e31819ed8d9. PubMed PMID: 19215272

96. Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis. 2007;79(2):149–52. PubMed PMID: 17388218

97. Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol. 2015. http://dx.doi.org/10.1016/j.jaad.2015.02.008. PubMed PMID: 25791801

98. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187–210. PubMed PMID: 17927284

99. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141(4):510–4. http://dx.doi.org/10.1001/archderm.141.4.510. PubMed PMID: 15837872

100. Wong JG, Toole JW, Demers AA, Musto G, Wiseman MC. Topical 5% imiquimod in the treatment of lentigo maligna. J Cutan Med Surg. 2012;16(4):245–9. PubMed PMID: 22784516

101. Woodmansee CS, McCall MW. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol Surg. 2009;35(8):1286–9. http://dx.doi.org/10.1111/j.1365-4725.2009.01227.x. PubMed PMID: 19577269

102. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002;146(6):1042–6. PubMed PMID: 12072074

103. Schmid-Wendtner MH, Brunner B, Konz B, Wendtner CM, Peter RU, Plewig G, Volkenandt M. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000;43(3):477–82. http://dx.doi.org/10.1067/mdo.2000.106241. PubMed PMID: 10954659

104. Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev. 2014;12:CD010308. http://dx.doi.org/10.1002/14651858.CD010308.pub2. PubMed PMID: 25526608

105. Huang CC. New approaches to surgery of lentigo maligna. Skin Therapy Lett. 2004;9(5):7–11. PubMed PMID: 15146261